Innoviva Profit Margin 2006-2019 | INVA

Current and historical gross margin, operating margin and net profit margin for Innoviva (INVA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Innoviva net profit margin as of December 31, 2019 is 60.35%.
Innoviva Annual Profit Margins
Innoviva Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.164B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $339.589B 14.84
Roche Holding AG (RHHBY) Switzerland $279.418B 0.00
Merck (MRK) United States $187.177B 14.22
Novartis AG (NVS) Switzerland $185.475B 15.44
Pfizer (PFE) United States $176.138B 10.76
Novo Nordisk (NVO) Denmark $141.488B 24.29
Eli Lilly (LLY) United States $130.559B 22.59
Bristol-Myers Squibb (BMY) United States $123.757B 11.74
AstraZeneca (AZN) United Kingdom $114.895B 24.73
AbbVie (ABBV) United States $108.417B 8.21
Sanofi (SNY) France $107.453B 12.77
GlaxoSmithKline (GSK) United Kingdom $92.874B 11.78
Bayer (BAYRY) Germany $52.894B 7.62
H Lundbeck (HLUYY) Denmark $5.897B 10.25